{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T04:21:10Z","timestamp":1771734070511,"version":"3.50.1"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":3371,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1093\/annonc\/mdq363","type":"journal-article","created":{"date-parts":[[2010,10,19]],"date-time":"2010-10-19T07:47:43Z","timestamp":1287474463000},"page":"vii313-vii319","source":"Crossref","is-referenced-by-count":37,"special_numbering":"S7","title":["Multiple myeloma"],"prefix":"10.1016","volume":"21","author":[{"given":"J.","family":"Blad\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Teresa Cibeira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq363_bb0010","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2141.1996.5191061.x","article-title":"Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years","volume":"93","author":"Blad\u00e9","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdq363_bb0015","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significant (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0020","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","article-title":"A monoclonal gammopathy precedes multiple myeloma in most patients","volume":"113","author":"Weis","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1093\/annonc\/mdq363_bb0025","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.1182\/blood-2009-03-207241","article-title":"Are all myelomas preceded by MGUS?","volume":"113","author":"Blad\u00e9","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0030","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1038\/leu.2008.203","article-title":"Pathogenesis and progression of monoclonal gammopathy of undetermined significance","volume":"22","author":"Blad\u00e9","year":"2008","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdq363_bb0035","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for classification of monoclonal gammopathies, multiple myeloma and related disorders","volume":"121","author":"International Myeloma Working Group","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdq363_bb0040","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2009.22.2257","article-title":"Smoldering (asymptomatic) multiple myeloma: current diagnostic criteria, new predictors of outcome and follow-up recommendations","volume":"28","author":"Blad\u00e9","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0045","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"Suppl 7","key":"10.1093\/annonc\/mdq363_bb0050","doi-asserted-by":"crossref","first-page":"vii117","DOI":"10.1093\/annonc\/mdn437","article-title":"Prognostic factors for multiple myeloma in the era of novel agents","volume":"19","author":"Blad\u00e9 Rosi\u00f1ol","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0055","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1182\/blood-2006-08-040410","article-title":"Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du My\u00e9lome","volume":"109","author":"Avet-Loiseau","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0060","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.leu.2404413","volume":"21","author":"Guti\u00e9rrez","year":"2007","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdq363_bb0065","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","article-title":"High-resolution genomic profiles defines distinct clinico-pathogenetic subgroups of multiple myeloma","volume":"4","author":"Carrasco","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1093\/annonc\/mdq363_bb0070","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1200\/JCO.2008.20.6136","article-title":"Prognostic significance of copy-number alterations in multiple myeloma","volume":"27","author":"Avet-Loiseau","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0075","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/sj.leu.2404442","article-title":"Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials","volume":"21","author":"Jagannath","year":"2007","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdq363_bb0080","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bmt.1702622","article-title":"High-dose therapy autotransplantation\/intensification vs. continued standard chemotherapy in multiple myeloma. Results of a non-randomized study from a single institution","volume":"26","author":"Blad\u00e9","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdq363_bb0085","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1038\/sj.bmt.1703035","article-title":"Impact of complete remission with intensive therapy in patients with responsive multiple myeloma","volume":"27","author":"Alexanian","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdq363_bb0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/sj.bmt.1704313","article-title":"High-dose therapy\/autologous stem cell transplantation in patients with chemosensitive myeloma: predictors of complete remission","volume":"33","author":"Nadal","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1093\/annonc\/mdq363_bb0095","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","article-title":"Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival","volume":"26","author":"Lahuerta","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0100","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3324\/haematol.11534","article-title":"Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma","volume":"92","author":"van de Velde","year":"2007","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdq363_bb0105","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0110","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1200\/JCO.2009.23.7172","article-title":"Major tumor shrinking and persistent molecular remission after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma","volume":"28","author":"Ladetto","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0115","first-page":"145","article-title":"National Cancer Institute. Proposed guidelines for protocol studies. II. Plasma cell myeloma","volume":"4","author":"Chronic Leukemia Myeloma Task Force","year":"1973","journal-title":"Cancer Chemother Rep"},{"key":"10.1093\/annonc\/mdq363_bb0120","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/1097-0142(197208)30:2<382::AID-CNCR2820300213>3.0.CO;2-C","article-title":"Combination chemotherapy for multiple myeloma","volume":"30","author":"Alexanian","year":"1972","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdq363_bb0125","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","article-title":"Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haematopoietic stem cell transplantation","volume":"102","author":"Blad\u00e9","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdq363_bb0130","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdq363_bb0135","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1200\/JCO.2007.11.6863","article-title":"Stem-cell transplantation for multiple myeloma in the era of novel drugs","volume":"26","author":"Bensinger","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0140","doi-asserted-by":"crossref","first-page":"5436","DOI":"10.1182\/blood-2009-07-204651","article-title":"How I treat multiple myeloma in younger patients","volume":"114","author":"Stewart","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0145","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1182\/blood-2009-08-238196","article-title":"Hematopoietic stem cell transplantation for multiple myeloma beyond 2010","volume":"115","author":"Blad\u00e9","year":"2010","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0150","first-page":"832","article-title":"Extramedullary multiple myeloma escapes the effect of thalidomide","volume":"89","author":"Rosi\u00f1ol","year":"2004","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdq363_bb0155","first-page":"1498","article-title":"Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma","volume":"91","author":"Harousseau","year":"2006","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdq363_bb0160","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1200\/JCO.2007.12.3323","article-title":"A phase II trial of alternating bortezomib and dexamethasone as induction regimen prior to autologous stem cell transplantation in younger patients with multiple myeloma","volume":"25","author":"Rosi\u00f1ol","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0165","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1365-2141.2008.06997.x","article-title":"Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up","volume":"141","author":"Popat","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdq363_bb0170","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1182\/blood.V114.22.351.351","article-title":"A phase III study of double autotransplantation incorporating bortezomib\/thalidomide\/dexamethasone (VTD) or thalidomide\/dexamethasone (TD) for multiple myeloma: superior clinical outcomes with VTD compared to TD","volume":"114","author":"Cavo","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1182\/blood.V114.22.130.130","article-title":"Thalidomide\/dexamethasone (TD) vs. bortezomibthalidomide\/dexamethasone (VTD) vs. VBMCP\/VBAD\/Velcade as induction regimens prior autologous stem cell transplantation in multiple myeloma. Results of a phase III PETHEMA\/GEM","volume":"114","author":"Rosi\u00f1ol","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0180","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1182\/blood-2006-05-022962","article-title":"Maintenance therapy with thalidomide improves survival in multiple myeloma patients","volume":"108","author":"Attal","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0185","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0190","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0195","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus allograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosi\u00f1ol","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0200","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1182\/blood-2008-07-167379","article-title":"Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo","volume":"113","author":"Bruno","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0205","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone or reduced-intensity autologous stem cell transplant in elderly patients with multiple myeloma (IFM 99-06): a randomized trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq363_bb0210","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0215","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: a randomized controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdq363_bb0220","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood.V110.11.78.78","article-title":"Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled phase III trial","volume":"110","author":"Waage","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0225","first-page":"241","article-title":"Melphalan\/prednisone\/thalidomide in induction therapy for multiple myeloma in elderly patients: final analysis of the Dutch cooperative Group HOVON 48 Study","volume":"112","author":"Wiejermans","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0230","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1182\/blood.V114.22.613.613","article-title":"A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with multiple myeloma","volume":"114","author":"Palumbo","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0235","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment for multiple myeloma","volume":"350","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq363_bb0240","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0245","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2007.14.1853","article-title":"A multicenter, randomized, double-blinded, placebo-controlled study of thalidomide plus dexamethasone versus dexamethasone as initial therapy for newly diagnosed multiple myeloma","volume":"26","author":"Rajkumar","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0250","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1200\/JCO.2005.03.0221","article-title":"Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Group","volume":"24","author":"Rajkumar","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0255","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomized clinical trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0260","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3324\/haematol.2008.002766","article-title":"Changing paradigms in the treatment of multiple myeloma","volume":"94","author":"Blad\u00e9","year":"2009","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdq363_bb0265","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","article-title":"Thalidomide for treatment of multiple myeloma: 10 years later","volume":"111","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0270","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase II study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq363_bb0275","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq363_bb0280","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0285","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0290","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1182\/blood-2008-12-196238","article-title":"Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdq363_bb0295","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq363_bb0300","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq363_bb0305","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/CCO.0b013e3283136984","article-title":"Advances in therapy of multiple myeloma","volume":"20","author":"Blad\u00e9","year":"2008","journal-title":"Curr Op Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0310","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/leu.2008.259","article-title":"Bone marrow microenvironment and the identification of new targets for myeloma therapy","volume":"23","author":"Podar","year":"2009","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdq363_bb0315","first-page":"120","article-title":"New drugs in multiple myeloma: mechanisms of action and phase i\/ii clinical findings","volume":"27","author":"Ocio","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0320","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3324\/haematol.2009.021550","article-title":"Novel drugs for the treatment of multiple myeloma","volume":"95","author":"Blad\u00e9","year":"2010","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdq363_bb0325","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdq363_bb0330","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues","author":"Delforge","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0335","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of biphosphonates in multiple myeloma: recommendations by an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq363_bb0340","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1200\/JCO.2007.14.3396","article-title":"Use of epoetin and darboepoetin in patients with cancer: 2007 American Society of Clinical Oncology\/American Society of Hematology clinical practice guideline update","volume":"26","author":"Rizzo","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419397042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419397042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/suppl_7\/vii313\/482891\/mdq363.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T18:16:12Z","timestamp":1635790572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419397042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":67,"alternative-id":["S0923753419397042"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq363","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}